New funding from leading strategic and existing investors comes amidst a 300% growth in members on the company's platform and the launch of its newest product for the long-term care insurance industryBOSTON
The Israeli drug development company, which has raised $22 million, is striving to harness combinatorial chemistry and AI to transform RNAi drug development into a programmable process.
/PRNewswire/ Eleven Therapeutics, a biotechnology company leading the AI revolution in nucleic acid therapeutics, announced today that it has raised a total.